ArticleScience advances2025
T-SCAPE: T cell immunogenicity scoring via cross-domain aided predictive engine.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026Review
- Engineering Immune Cell to Counteract Aging and Aging-Associated Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Artificial intelligence-driven nano-enhanced stem cell therapy for neurodegenerative diseases: from rational design to clinical translation.Journal of nanobiotechnology · 2026Review
- HLA class I-naturally presented synovial tissue peptides are recognized by CD8+ T lymphocytes from rheumatoid arthritis patients.Frontiers in immunology · 2026Article
- Artificial intelligence for coordinating vaccine design, antiviral discovery, and real-world monitoring in the era of emerging and endemic viral threats.Frontiers in pharmacology · 2026Review
- Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell immunogenicity, the ability of peptide fragments to elicit T cell responses, is a critical determinant of the safety and efficacy of protein therapeutics and vaccines. While deep learning shows promise for in silico prediction, the scarcity of comprehensive immunogenicity data is a major challenge. We present T cell immunogenicity scoring via cross-domain aided predictive engine (T-SCAPE), a novel multidomain deep learning framework that leverages adversarial domain adaptation to integrate diverse immunologically relevant data sources, including major histocompatibility complex (MHC) presentation, peptide-MHC (pMHC) binding affinity, T cell receptor-pMHC interaction, source organism information, and T cell activation. Validated through rigorous leakage-controlled benchmarks, T-SCAPE demonstrates exceptional performance in predicting T cell activation for specific peptide-MHC pairs. It also accurately predicts the antidrug antibody-inducing potential of therapeutic antibodies without requiring MHC inputs. This success is attributed to T-SCAPE's biologically grounded and data-driven multidomain pretraining. Its consistent and robust performance highlights its potential to advance the development of safer and more effective vaccines and protein therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.